A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial

BACKGROUND: This phase I study aimed to evaluate the safety, peptide-specific immune responses, and anti-tumor effects of a novel vaccination therapy comprising multi-HLA-binding heat shock protein (HSP) 70/glypican-3 (GPC3) peptides and a novel adjuvant combination of hLAG-3Ig and Poly-ICLC against...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakajima, Masao, Hazama, Shoichi, Tamada, Koji, Udaka, Keiko, Kouki, Yasunobu, Uematsu, Toshinari, Arima, Hideki, Saito, Akira, Doi, Shun, Matsui, Hiroto, Shindo, Yoshitaro, Matsukuma, Satoshi, Kanekiyo, Shinsuke, Tokumitsu, Yukio, Tomochika, Shinobu, Iida, Michihisa, Yoshida, Shin, Nakagami, Yuki, Suzuki, Nobuaki, Takeda, Shigeru, Yamamoto, Shigeru, Yoshino, Shigefumi, Ueno, Tomio, Nagano, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347520/
https://www.ncbi.nlm.nih.gov/pubmed/32219501
http://dx.doi.org/10.1007/s00262-020-02518-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347520/
https://www.ncbi.nlm.nih.gov/pubmed/32219501
http://dx.doi.org/10.1007/s00262-020-02518-7

Ejemplares similares